Cargando…
Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis
Cancer immunotherapy, in the form of vaccination, adoptive cellular transfer, or immune checkpoint inhibitors, has emerged as a promising practice within the field of oncology. However, despite the developing field's potential to revolutionize cancer treatment, the presence of immunotherapeutic...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Immunologists
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049583/ https://www.ncbi.nlm.nih.gov/pubmed/32158595 http://dx.doi.org/10.4110/in.2020.20.e7 |
_version_ | 1783502468131323904 |
---|---|
author | Oh, Se Jin Lee, Jaeyoon Kim, Yukang Song, Kwon-Ho Cho, Eunho Kim, Minsung Jung, Heejae Kim, Tae Woo |
author_facet | Oh, Se Jin Lee, Jaeyoon Kim, Yukang Song, Kwon-Ho Cho, Eunho Kim, Minsung Jung, Heejae Kim, Tae Woo |
author_sort | Oh, Se Jin |
collection | PubMed |
description | Cancer immunotherapy, in the form of vaccination, adoptive cellular transfer, or immune checkpoint inhibitors, has emerged as a promising practice within the field of oncology. However, despite the developing field's potential to revolutionize cancer treatment, the presence of immunotherapeutic-resistant tumor cells in many patients present a challenge and limitation to these immunotherapies. These cells not only indicate immunotherapeutic resistance, but also show multi-modal resistance to conventional therapies, abnormal metabolism, stemness, and metastasis. How can immunotherapeutic-resistant tumor cells render multi-malignant phenotypes? We reasoned that the immune-refractory phenotype could be associated with multi-malignant phenotypes and that these phenotypes are linked together by a factor that acts as the master regulator. In this review, we discussed the role of the embryonic transcription factor NANOG as a crucial master regulator we named “common factor” in multi-malignant phenotypes and presented strategies to overcome multi-malignancy in immunotherapeutic-resistant cancer by restraining the NANOG-mediated multi-malignant signaling axis. Strategies that blunt the NANOG axis could improve the clinical management of therapy-refractory cancer. |
format | Online Article Text |
id | pubmed-7049583 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Korean Association of Immunologists |
record_format | MEDLINE/PubMed |
spelling | pubmed-70495832020-03-10 Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis Oh, Se Jin Lee, Jaeyoon Kim, Yukang Song, Kwon-Ho Cho, Eunho Kim, Minsung Jung, Heejae Kim, Tae Woo Immune Netw Review Article Cancer immunotherapy, in the form of vaccination, adoptive cellular transfer, or immune checkpoint inhibitors, has emerged as a promising practice within the field of oncology. However, despite the developing field's potential to revolutionize cancer treatment, the presence of immunotherapeutic-resistant tumor cells in many patients present a challenge and limitation to these immunotherapies. These cells not only indicate immunotherapeutic resistance, but also show multi-modal resistance to conventional therapies, abnormal metabolism, stemness, and metastasis. How can immunotherapeutic-resistant tumor cells render multi-malignant phenotypes? We reasoned that the immune-refractory phenotype could be associated with multi-malignant phenotypes and that these phenotypes are linked together by a factor that acts as the master regulator. In this review, we discussed the role of the embryonic transcription factor NANOG as a crucial master regulator we named “common factor” in multi-malignant phenotypes and presented strategies to overcome multi-malignancy in immunotherapeutic-resistant cancer by restraining the NANOG-mediated multi-malignant signaling axis. Strategies that blunt the NANOG axis could improve the clinical management of therapy-refractory cancer. The Korean Association of Immunologists 2020-01-20 /pmc/articles/PMC7049583/ /pubmed/32158595 http://dx.doi.org/10.4110/in.2020.20.e7 Text en Copyright © 2020. The Korean Association of Immunologists https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Oh, Se Jin Lee, Jaeyoon Kim, Yukang Song, Kwon-Ho Cho, Eunho Kim, Minsung Jung, Heejae Kim, Tae Woo Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis |
title | Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis |
title_full | Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis |
title_fullStr | Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis |
title_full_unstemmed | Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis |
title_short | Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis |
title_sort | far beyond cancer immunotherapy: reversion of multi-malignant phenotypes of immunotherapeutic-resistant cancer by targeting the nanog signaling axis |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049583/ https://www.ncbi.nlm.nih.gov/pubmed/32158595 http://dx.doi.org/10.4110/in.2020.20.e7 |
work_keys_str_mv | AT ohsejin farbeyondcancerimmunotherapyreversionofmultimalignantphenotypesofimmunotherapeuticresistantcancerbytargetingthenanogsignalingaxis AT leejaeyoon farbeyondcancerimmunotherapyreversionofmultimalignantphenotypesofimmunotherapeuticresistantcancerbytargetingthenanogsignalingaxis AT kimyukang farbeyondcancerimmunotherapyreversionofmultimalignantphenotypesofimmunotherapeuticresistantcancerbytargetingthenanogsignalingaxis AT songkwonho farbeyondcancerimmunotherapyreversionofmultimalignantphenotypesofimmunotherapeuticresistantcancerbytargetingthenanogsignalingaxis AT choeunho farbeyondcancerimmunotherapyreversionofmultimalignantphenotypesofimmunotherapeuticresistantcancerbytargetingthenanogsignalingaxis AT kimminsung farbeyondcancerimmunotherapyreversionofmultimalignantphenotypesofimmunotherapeuticresistantcancerbytargetingthenanogsignalingaxis AT jungheejae farbeyondcancerimmunotherapyreversionofmultimalignantphenotypesofimmunotherapeuticresistantcancerbytargetingthenanogsignalingaxis AT kimtaewoo farbeyondcancerimmunotherapyreversionofmultimalignantphenotypesofimmunotherapeuticresistantcancerbytargetingthenanogsignalingaxis |